Cetera Investment Advisers
AEON icon

Cetera Investment Advisers’s AEON Biopharma AEON Stock Holding History

Cetera Investment Advisers’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-166
Closed -$12.5K – 3768
2024
Q3 		$12.5K Buy
+166
New +$14.6K ﹤0.01% 3661

Other funds holding AEON

BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CG
Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Investment Advisers's AEON Position: Q4 2024 in Review

Cetera Investment Advisers sold out of AEON Biopharma (AEON) in Q4 2024, closing a stake of 166 shares — an estimated $12.5K sold.

Cetera Investment Advisers first reported a position in AEON in Q3 2024 and held it in 1 quarter. The position peaked at $12.5K in Q3 2024. 37 funds tracked by Wall St. Rank hold AEON as of Q4 2024.

  • Cetera Investment Advisers reported no remaining AEON Biopharma position as of Q4 2024 after selling out during the quarter.
  • Cetera Investment Advisers sold 166 AEON Biopharma shares in Q4 2024, an estimated $12.5K.
  • Cetera Investment Advisers first reported a position in AEON Biopharma in Q3 2024 and held it in 1 quarter.
  • Cetera Investment Advisers's AEON Biopharma position peaked at $12.5K in Q3 2024.
  • 37 funds tracked by Wall St. Rank held AEON Biopharma as of Q4 2024.

Based on Cetera Investment Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.